PBMC Vaccine Loading α-GC and Antigen Without Cell Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including immunotherapy using dendritic cells and B cells, face challenges such as limited availability, complex isolation processes, and reduced immunogenicity, limiting their widespread use in cancer vaccines.
Innovation Solution
A vaccine comprising peripheral blood mononuclear cells (PBMCs) loaded with natural killer T cell ligands and antigens, particularly alpha-galactosylceramide (α-GC), which induces synergistic immune responses without the need for isolating specific cell types, enhancing immune activation and cytotoxic T lymphocyte responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cells are used as antigen-presenting cells, then immune activation is strong, but cell availability is limited and isolation is complex
Solution Approach 1:
The patent extracts the essential function of dendritic cells (antigen presentation) and transfers it to B cells. By loading B cells with cancer antigens and α-GC, the patent achieves strong immune activation without needing to isolate and culture dendritic cells, thus simplifying the manufacturing process while maintaining therapeutic effectiveness
Solution Approach 2:
The patent uses B cells as intermediary cells that can be easily obtained from peripheral blood. These B cells are loaded with antigens and α-GC to serve as functional substitutes for dendritic cells, enabling strong immune responses through a simpler, more scalable cell source
2Ease of manufacture
If B cells are used as antigen-presenting cells, then cell availability is high, but immunogenicity is weak
Solution Approach 1:
The patent creates a composite functional unit by combining B cells with two key components: cancer antigens and α-GC (a natural killer T cell ligand). This composite structure enables B cells to simultaneously present antigens and activate natural killer T cells, dramatically enhancing their immunogenicity while retaining their ease of availability
Solution Approach 2:
The patent changes the functional parameters of B cells by loading them with α-GC and cancer antigens. This transformation converts B cells from having weak immunogenicity to becoming potent antigen-presenting cells that can strongly activate T cells and natural killer cells, while maintaining their high availability from peripheral blood
3Reliability
If specific cell types are isolated for vaccine production, then cell function is optimized, but processing complexity increases
Solution Approach 1:
The patent uses B cells as a universal cell type that can be obtained from peripheral blood without complex isolation procedures. By loading B cells with antigens and α-GC, the patent enables them to perform multiple functions: antigen presentation, natural killer T cell activation, and induction of cytotoxic T cell responses, thereby achieving optimized cell function through a simple, single-step processing approach
Data Source
AI summary
The present invention relates to an immunoprophylactic and therapeutic vaccine comprising peripheral blood mononuclear cells loaded with a natural killer T cell ligand and an antigen, and specifically, to an immunotherapeutic vaccine comprising peripheral blood mononuclear cells loaded with alpha-galactosylceramide, a natural killer T cell ligand and a type of glycolipid. A composition of the present invention is easy to obtain because there is no need to separate specific cells from peripheral blood mononuclear cells. In addition, immunization of peripheral blood mononuclear cells loaded with a natural killer T cell ligand and an antigen not only induces significant levels of activation of natural killer cells and natural killer T cells and cytotoxic T lymphocyte responses, but also has a synergistic effect in the treatment of malignant tumors and thus can be helpfully used as an anticancer immunotherapeutic agent.